<SEC-DOCUMENT>0000921669-21-000011.txt : 20210224
<SEC-HEADER>0000921669-21-000011.hdr.sgml : 20210224
<ACCEPTANCE-DATETIME>20210224082712
ACCESSION NUMBER:		0000921669-21-000011
CONFORMED SUBMISSION TYPE:	SC 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20210224
DATE AS OF CHANGE:		20210224

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bausch Health Companies Inc.
		CENTRAL INDEX KEY:			0000885590
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-45947
		FILM NUMBER:		21668615

	BUSINESS ADDRESS:	
		STREET 1:		2150 ST. ELZEAR BLVD. WEST
		STREET 2:		LAVAL
		CITY:			QUEBEC
		STATE:			A8
		ZIP:			H7L 4A8
		BUSINESS PHONE:		514-744-6792

	MAIL ADDRESS:	
		STREET 1:		2150 ST. ELZEAR BLVD. WEST
		STREET 2:		LAVAL
		CITY:			QUEBEC
		STATE:			A8
		ZIP:			H7L 4A8

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Valeant Pharmaceuticals International, Inc.
		DATE OF NAME CHANGE:	20100928

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOVAIL Corp
		DATE OF NAME CHANGE:	20100416

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOVAIL CORP INTERNATIONAL
		DATE OF NAME CHANGE:	19960522

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ICAHN CARL C
		CENTRAL INDEX KEY:			0000921669
		STANDARD INDUSTRIAL CLASSIFICATION:	UNKNOWN SIC - 0000 [0000]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		C/O ICAHN ENTERPRISES L.P.
		STREET 2:		16690 COLLINS AVE., PH-1
		CITY:			SUNNY ISLES BEACH
		STATE:			FL
		ZIP:			33160
		BUSINESS PHONE:		305-422-4145

	MAIL ADDRESS:	
		STREET 1:		C/O ICAHN ENTERPRISES L.P.
		STREET 2:		16690 COLLINS AVE., PH-1
		CITY:			SUNNY ISLES BEACH
		STATE:			FL
		ZIP:			33160

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ICAHN CARL C ET AL
		DATE OF NAME CHANGE:	19950612
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13D/A
<SEQUENCE>1
<FILENAME>hbcsc13da02242021.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Icahn
         Document created using EDGARfilings PROfile 7.2.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: center;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center;">Washington, D.C. 20549</div>
    <div><br>
    </div>
    <div style="text-align: center;">SCHEDULE 13D</div>
    <div><br>
    </div>
    <div style="text-align: center;">Under the Securities Exchange Act of 1934</div>
    <div style="text-align: center;">(Amendment No. 1)*</div>
    <div><br>
    </div>
    <div style="text-align: center;">Bausch Health Companies Inc.</div>
    <div style="text-align: center;">(Name of Issuer)</div>
    <div><br>
    </div>
    <div style="text-align: center;">Common Stock, no par value</div>
    <div style="text-align: center;">(Title of Class of Securities)</div>
    <div><br>
    </div>
    <div style="text-align: center;">071734107<br>
      (CUSIP Number)</div>
    <div><br>
    </div>
    <div style="text-align: center;">Andrew Langham</div>
    <div style="text-align: center;">Icahn Capital LP</div>
    <div style="text-align: center;">16690 Collins Avenue<br>
      Sunny Isles Beach, FL 33160</div>
    <div style="text-align: center;">(305) 422-4100</div>
    <div><br>
    </div>
    <div style="text-align: center;">(Name, Address and Telephone Number of Person Authorized to</div>
    <div style="text-align: center;">Receive Notices and Communications)</div>
    <div><br>
    </div>
    <div style="text-align: center;">February 23, 2021</div>
    <div style="text-align: center;">(Date of Event which Requires Filing of this Statement)</div>
    <div><br>
    </div>
    <div style="text-align: justify;">If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing
      this schedule because of Section 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box / /.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d&#8209;7 for other
      parties to whom copies are to be sent.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities,
      and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act
      of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify;">SCHEDULE 13D</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Item 1. Security and Issuer</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">This statement constitutes Amendment No. 1 to the Schedule 13D relating to the shares of Common Stock, no par value (&#8220;Shares&#8221;), issued
      by Bausch Health Companies Inc. (the &#8220;Issuer&#8221;), and hereby amends the Schedule 13D filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on February 11, 2021 (the &#8220;Schedule 13D&#8221;), to furnish the additional information set forth herein. All
      capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Item 4. Purpose of Transaction</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Item 4 of the Schedule 13D is hereby amended to add the following:</div>
    <div><br>
    </div>
    <div style="text-align: justify;">On February 23, 2021, the Reporting Persons entered into a Director Appointment and Nomination Agreement (the "Nomination Agreement") with the Issuer. In
      addition, on February 24, 2021, the Issuer issued a press release (the "Press Release") related to the Nomination</div>
    <div style="text-align: justify;">Agreement. Copies of the Nomination Agreement and Press Release are filed herewith as exhibits and incorporated herein by reference.</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">Item 6. Contracts, Arrangements, Understandings or Relationship with Respect to Securities of the Issuer</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Item 6 of the Schedule 13D is hereby amended by adding the following:</div>
    <div><br>
    </div>
    <div style="text-align: justify;">The disclosure set forth above in Item 4 is incorporated herein by reference.</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">Item 7. Material to be Filed as Exhibits</div>
    <div><br>
    </div>
    <div style="text-align: justify;">1. Director Appointment and Nomination Agreement among the Reporting Persons and the Issuer (incorporated by reference to Exhibit 10.1 to the Form 8&#8722;K
      filed by the Issuer with the Securities and Exchange Commission on February 24, 2021).</div>
    <div><br>
    </div>
    <div style="text-align: justify;">2. Press Release issued by the Issuer on February 24, 2021 (incorporated by reference to Exhibit 99.1 to the Form 8&#8722;K filed by the Issuer with the
      Securities and Exchange Commission on February 24, 2021).</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center;">SIGNATURE</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">After reasonable inquiry and to the best of each of the undersigned knowledge and belief, each of the undersigned certifies that the
      information set forth in this statement is true, complete and correct.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Dated: February 24, 2021</div>
    <div><br>
    </div>
    <div style="text-align: justify;">ICAHN PARTNERS MASTER FUND LP</div>
    <div style="text-align: justify;">ICAHN OFFSHORE LP</div>
    <div style="text-align: justify;">ICAHN PARTNERS LP</div>
    <div style="text-align: justify;">ICAHN ONSHORE LP</div>
    <div style="text-align: justify;">BECKTON CORP.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">By:<font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><u>/s/ Irene March</u></div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">Name: Irene March</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">Title: Chief Compliance Officer</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">ICAHN CAPITAL LP</div>
    <div style="text-align: justify; text-indent: 36pt;">By: IPH GP LLC, its general partner</div>
    <div style="text-align: justify; text-indent: 36pt;">By: Icahn Enterprises Holdings L.P., its sole member</div>
    <div style="text-align: justify; text-indent: 36pt;">By: Icahn Enterprises G.P. Inc., its general partner</div>
    <div style="text-align: justify;">IPH GP LLC</div>
    <div style="text-align: justify; text-indent: 36pt;">By: Icahn Enterprises Holdings L.P., its sole member</div>
    <div style="text-align: justify; text-indent: 36pt;">By: Icahn Enterprises G.P. Inc., its general partner</div>
    <div style="text-align: justify;">ICAHN ENTERPRISES HOLDINGS L.P.</div>
    <div style="text-align: justify; text-indent: 36pt;">By: Icahn Enterprises G.P. Inc., its general partner</div>
    <div style="text-align: justify;">ICAHN ENTERPRISES G.P. INC.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">By:<font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><u>/s/ SungHwan Cho</u></div>
    <div style="text-align: justify; text-indent: 36pt;">Name: SungHwan Cho</div>
    <div style="text-align: justify; text-indent: 36pt;">Title: Chief Financial Officer</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;"><u>/s/ Carl C. Icahn</u><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 108pt">&#160;</font></div>
    <div style="text-align: justify;">CARL C. ICAHN</div>
    <div><br>
    </div>
    <div style="text-align: center;">[Signature Page of Schedule 13D/A No. 1 &#8211; Bausch Health Companies Inc.]</div>
    <div><br>
    </div>
    <div><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
